Lexicon Pharmaceuticals (NASDAQ:LXRX) CEO Purchases 30,064 Shares of Stock

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) CEO Michael Exton bought 30,064 shares of the business’s stock in a transaction on Friday, November 6th. The shares were acquired at an average price of $1.66 per share, with a total value of $49,906.24. Following the transaction, the chief executive officer directly owned 328,496 shares of the company’s stock, valued at approximately $545,303.36. This trade represents a 10.07% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Lexicon Pharmaceuticals Stock Performance

NASDAQ LXRX opened at $1.78 on Monday. The company’s 50 day moving average is $1.81 and its 200-day moving average is $1.89. Lexicon Pharmaceuticals, Inc. has a 12-month low of $1.10 and a 12-month high of $2.68. The company has a quick ratio of 10.56, a current ratio of 10.62 and a debt-to-equity ratio of 0.32. The firm has a market cap of $792.02 million, a P/E ratio of -12.71 and a beta of 1.10.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.03. The company had revenue of $11.25 million for the quarter, compared to analysts’ expectations of $4.14 million. Lexicon Pharmaceuticals had a negative net margin of 161.80% and a negative return on equity of 35.76%. Sell-side analysts predict that Lexicon Pharmaceuticals, Inc. will post -0.16 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Siren L.L.C. boosted its holdings in Lexicon Pharmaceuticals by 13.8% in the 1st quarter. Siren L.L.C. now owns 44,303,518 shares of the biopharmaceutical company’s stock valued at $69,113,000 after purchasing an additional 5,384,615 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Lexicon Pharmaceuticals by 508.0% in the first quarter. Renaissance Technologies LLC now owns 1,600,500 shares of the biopharmaceutical company’s stock worth $2,497,000 after purchasing an additional 1,337,246 shares during the period. Bank of New York Mellon Corp bought a new position in shares of Lexicon Pharmaceuticals in the second quarter worth $1,365,000. Bank of America Corp DE increased its holdings in shares of Lexicon Pharmaceuticals by 415.3% in the first quarter. Bank of America Corp DE now owns 526,103 shares of the biopharmaceutical company’s stock worth $821,000 after purchasing an additional 424,006 shares during the period. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Lexicon Pharmaceuticals in the first quarter worth $1,170,000. 74.70% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Zacks Research lowered Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, August 3rd. Wall Street Zen upgraded Lexicon Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Sunday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research note on Wednesday, October 21st. Finally, Cantor Fitzgerald initiated coverage on Lexicon Pharmaceuticals in a report on Monday, September 28th. They set an “overweight” rating and a $8.00 price objective on the stock. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $5.70.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious and chronic diseases. The company uses its drug discovery platform to identify small-molecule treatments designed to target specific biological pathways, with an emphasis on metabolic, cardiovascular and neurological conditions.

Lexicon’s commercial products include INPEFA (sotagliflozin), an oral medicine approved in the United States to reduce the risk of cardiovascular death, hospitalization for heart failure and urgent heart-failure visits in certain adults with heart failure or type 2 diabetes and chronic kidney disease.